Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial.

OBJECTIVE--To study the effect of epoprostenol (prostacyclin, PGI2) given before, during, and for 36 h after coronary angioplasty on restenosis at six months and to evaluate the transcardiac gradient of platelet aggregation before and after percutaneous transluminal coronary angioplasty (PTCA) in tr...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Gershlick, A. H., Spriggins, D., Davies, S. W., Syndercombe Court, Y. D., Timmins, J., Timmis, A. D., Rothman, M. T., Layton, C., Balcon, R.
Format: Artigo
Jezik:Inglês
Izdano: 1994
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC483601/
https://ncbi.nlm.nih.gov/pubmed/8297699
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki